Professor
Clayton Foundation Laboratories for Peptide Biology
J.W. Kieckhefer Foundation Chair
Sugar production switch in liver may offer target for new diabetes therapies
Salk researchers find molecular switch that controls liver glucose production and may represent a new avenue for treating insulin-resistant type II diabetes. Read more »
In addition to fast food, desk jobs, and inertia, there is one more thing to blame for unwanted pounds-our genome, which has apparently not caught up with the fact that we no longer live in the Stone Age.
That is one conclusion drawn by researchers at the Salk Institute for Biological Studies, who recently showed that mice lacking a gene regulating energy balance are protected from weight gain, even on a high fat diet. These findings have implications for the worldwide obesity epidemic and its consequences, such as type two diabetes. Read more »
Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.
Their discovery, published in the September 19 advance online edition of the journal Nature Medicine, provides an entirely new biochemical approach for scientists to develop treatments for obesity and type 2 diabetes. It also raises the interesting possibility that some of the rise in diabetes in the U.S. and other major industrialized countries could be a consequence of disturbances in sleep-wake cycles from our increasingly around-the-clock lifestyles. Read more »
BS, Biochemistry, Harvard University
MD, PhD, Physiology, Tufts University School of Medicine
Research Fellow in Medicine, Tufts-New England Medical Center, Boston
Your partnership allows our scientists to accelerate the pace of high-risk, high-reward discoveries that have the potential to benefit the health of all humanity-be it cancer, Alzheimer’s disease, climate change, infectious diseases or more.
